Open H, Mitsui Chemicals, Mitsubishi Chemical G, WOWOW (15 days) (1380-4990)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/15 (Wed) <1380>Akigawa Pasture <1446>Candyle<1447>itbookHD <145A>ELISBE<148A>Hatch Work <149A>Shinka <150A>JSH <1514>Residence
Digital Plus, Genie, etc.
<2370>Medinet Co., Ltd. Macquarie Bank Limited Stock Ownership Ratio 5.55% → 4.49% Reporting Obligation Date 2024/04/22 <369>Digital Plus McCauley Bank Limited Stock Ownership Ratio 15.79% → 14.54% Reporting Obligation Date 2024/04/09 <3905>Data Section Hayashi Kento Co., Ltd. Stock Ownership Ratio 7.13% → 4.95%
CHATWORK, DREAM ARTS, etc.
<4431>Smarregi Wishbone Management LP Co., Ltd. (WISHBONE MANAGEMENT LP) Stock Ownership Ratio 5.28% → 6.70% Reporting Obligation Date 2024/04/15 <4448>CHATWORK CO., LTD. Asset Management One Co., Ltd. Stock Ownership Ratio 7.82% → 5.90% Reporting Obligation Date 2024/04/15 <4597>Solasia Pharma Shares
FINATEXT, TASKI HD, etc.
<166a>Acquired shares of Aura, which handles the TASKI HD Asset Consulting business, and made it a subsidiary <4419>FinATEXT upward revision, previous fiscal year operating profit forecast 220 million yen ← 0.21 billion yen <4564>OTS acquisition/cancellation of all remaining 35th stock acquisition rights (with exercise price correction clauses) <4586>Medlec 28th Stock Acquisition Rights (with exercise price correction clauses) from the 11th, 570,000 shares <4597>Number one 14th Stock Acquisition Rights (exercise)
APPBANK, GENDA, etc.
<3133>Kaiho LLC Arrow Energy Stock Ownership Ratio 5.27% → 1.39% Reporting Obligation Date 2024/04/05 <3133>Kaiho Yamada Toru Co., Ltd. Stock Ownership Ratio 10.84% → 12.99% Reporting Obligation Date 2024/04/05 <3558>Jade Group Co., Ltd. Tanaka Yusuke Stock Holding Ratio 13.05% → 13.08% Reporting Obligation Date 2024/04/08<4
LIS B, GOOD SPEED, etc.
<145A>LIS B Co., Ltd. Daiwa Enterprise Investment Co., Ltd. Stock Ownership Ratio -% → 5.38% Reporting Obligation Date 2024/03/26 <145A>LIS B Co., Ltd. Change Holdings Stock Ownership Ratio -% → 6.05% Reporting Obligation Date 2024/03/26 <145A>LIS B Co., Ltd. Well Side Co., Ltd. Stock Ownership Ratio -% → 36.81% Reporting Obligation Date
Solasia, Platz, etc.
<4597>Number of shares issued from 3 days of mass exercise of Solasia's 14th Stock Acquisition Rights (with exercise price amendment clauses), 5.5 million shares <7813>Establishment of a joint venture through a business alliance and joint investment with Qingdao Haier Home Artificial intelligence industry innovation center Co., Ltd. (China), a group company of the Platz Haier Group
Volume change rate ranking (around 9 o'clock) ~ Asahi, Shimamura, etc. are ranked
* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [4/2 9:32 as of 9:32] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate Stock Price Change Rate <2647> NF US Bonds 7 30000 107185.08 395.99% -0.0092
Zingib, LIS B, etc.
<142A>Jinjib Co., Ltd. Mitsubishi UFJ Trust and Banking Co., Ltd. Stock Ownership Ratio 9.48% → 7.81% Reporting Obligation Date 2024/03/25 <145A>LIS B Daiwa Enterprise Investment Co., Ltd. Stock Ownership Ratio -% → 5.38% Reporting Obligation Occurrence Date 2024/03/26 <145A>LI B Co., Ltd. Well Side Co., Ltd. Stock Ownership Ratio -% → 36.81% Reporting Obligation Occurrence Date 2
Clear, Nippon Denki, etc. [5% rule for emerging markets]
<147A>Soracom KDDI Co., Ltd. Stock Ownership Ratio -% → 44.43% Reporting Obligation Date 2024/03/26 <150A>JSH Co., Ltd. Noguchi Kazuki Stock Ownership Ratio -% → 36.15% Reporting Obligation Date 2024/03/26 <2998>Clear Co., Ltd. SBI Holdings Co., Ltd. Stock Ownership Ratio 21.37% → 20.36% Reporting Obligation Date 2024/03/19<
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains
Solasia Pharma (TYO:4597) reduced its nine-month attributable loss, thanks to improved revenue and lower research and development, and selling, general, and administrative expenses. The drug developer
No Data